Characteristics of patients with BOS
| . | At onset of BOS (n = 46) . | At maximum grade of BOS (n = 46) . |
|---|---|---|
| n (%) | ||
| NIH-defined cGVHD lung severity score | ||
| 1 | 25 (54) | 16 (35) |
| 2 | 18 (39) | 21 (45) |
| 3 | 3 (7) | 9 (20) |
| LFS | ||
| 0 (< 3) | 1 (2) | 0 |
| 1 (3-5) | 11 (24) | 9 (20) |
| 2 (6-9) | 31 (67) | 28 (60) |
| 3 (10-12) | 3 (7) | 9 (20) |
| Median LFS, range | 7 (2-10) | 8 (4-12) |
| Lung symptoms scale* | ||
| 0 | 37 (80) | 14 (30) |
| 1 | 9 (20) | 21 (46) |
| 2 | 0 | 8 (17) |
| 3 | 0 | 3 (7) |
| Median FEV1, range | 61 (36-75) | 52 (16-75) |
| Patients with FEV1 decline >10% | 42 (91) | 46 (100) |
| Patients with FEV1 ≤55% | 12 (26) | 23 (50) |
| Median FEV1/SVC ratio, range | 0.69 (0.41-0.94) | 0.62 (0.22-0.88) |
| Patients with FEV1/SVC ratio <0.7 | 25 (54) | 28 (61) |
| Median RV %, range | 136 (71-222) | 145 (63-270) |
| Patients with RV >120% | 32 (70) | 35 (76) |
| Median RV/TLC ratio, range | 137 (96-208) | 136 (85-223) |
| Patients with RV/TLC >120% | 32 (70) | 32 (70) |
| NIH-defined HR-CT changes | ||
| Air trapping | 35 (76)** | 39 (85) |
| Bronchiectasis | 2 (4) | 7 (15) |
| Small airway thickening | 25 (54) | 36 (78) |
| Transbronchial biopsies | ||
| Constrictive bronchiolitis | 23/36 (64) | |
| Alveolitis | 13/36 (36) | |
| Median time from d 0 to BOS, mo, range | 11 (3-30) | |
| Median therapies, range | 2.5 (1-7) | |
| . | At onset of BOS (n = 46) . | At maximum grade of BOS (n = 46) . |
|---|---|---|
| n (%) | ||
| NIH-defined cGVHD lung severity score | ||
| 1 | 25 (54) | 16 (35) |
| 2 | 18 (39) | 21 (45) |
| 3 | 3 (7) | 9 (20) |
| LFS | ||
| 0 (< 3) | 1 (2) | 0 |
| 1 (3-5) | 11 (24) | 9 (20) |
| 2 (6-9) | 31 (67) | 28 (60) |
| 3 (10-12) | 3 (7) | 9 (20) |
| Median LFS, range | 7 (2-10) | 8 (4-12) |
| Lung symptoms scale* | ||
| 0 | 37 (80) | 14 (30) |
| 1 | 9 (20) | 21 (46) |
| 2 | 0 | 8 (17) |
| 3 | 0 | 3 (7) |
| Median FEV1, range | 61 (36-75) | 52 (16-75) |
| Patients with FEV1 decline >10% | 42 (91) | 46 (100) |
| Patients with FEV1 ≤55% | 12 (26) | 23 (50) |
| Median FEV1/SVC ratio, range | 0.69 (0.41-0.94) | 0.62 (0.22-0.88) |
| Patients with FEV1/SVC ratio <0.7 | 25 (54) | 28 (61) |
| Median RV %, range | 136 (71-222) | 145 (63-270) |
| Patients with RV >120% | 32 (70) | 35 (76) |
| Median RV/TLC ratio, range | 137 (96-208) | 136 (85-223) |
| Patients with RV/TLC >120% | 32 (70) | 32 (70) |
| NIH-defined HR-CT changes | ||
| Air trapping | 35 (76)** | 39 (85) |
| Bronchiectasis | 2 (4) | 7 (15) |
| Small airway thickening | 25 (54) | 36 (78) |
| Transbronchial biopsies | ||
| Constrictive bronchiolitis | 23/36 (64) | |
| Alveolitis | 13/36 (36) | |
| Median time from d 0 to BOS, mo, range | 11 (3-30) | |
| Median therapies, range | 2.5 (1-7) | |
LFS, lung function score; RV, residual volume; SVC, slow vital capacity; TLC, total lung capacity.
Symptoms reported by the patients as published by Filipovich and colleagues.5 This score distinguished between no symptoms, mild symptoms (shortness of breath after climbing one flight of steps), moderate symptoms (shortness of breath after walking on flat ground), and severe symptoms (shortness of breath at rest, requiring O2).
In 3 patients HR-CT scan of the lungs was not valuable due to poor patient compliance.
Transbronchial biopsies were performed in 41 patients; however, valid diagnosis of biopsy specimens was possible in only 36 patients.